| B3galt5 deficiency attenuates hepatocellular carcinoma by suppressing mTOR/p70s6k-mediated glycolysis. | B3galt5 deficiency attenuates hepatocellular carcinoma by suppressing mTOR/p70s6k-mediated glycolysis.
Zhang X, Liu H, Wang H, Zhao R, Lu Q, Liu Y, Han Y, LuluRen, Pan H, Han W., Free PMC Article | 12/17/2022 |
| High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer. | High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.
Liao YM, Wang YH, Hung JT, Lin YJ, Huang YL, Liao GS, Hsu YL, Wu JC, Yu AL., Free PMC Article | 01/8/2022 |
| Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer. | Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer.
Ding Y, Feng W, Ge JK, Dai L, Liu TT, Hua XY, Lu X, Ju SQ, Yu J. | 02/2/2021 |
| SSEA3 and Sialyl Lewis a Glycan Expression Is Controlled by B3GALT5 LTR through Lamin A-NFYA and SIRT1-STAT3 Signaling in Human ES Cells. | SSEA3 and Sialyl Lewis a Glycan Expression Is Controlled by B3GALT5 LTR through Lamin A-NFYA and SIRT1-STAT3 Signaling in Human ES Cells.
Cai BH, Lee HY, Chou CK, Wu PH, Huang HC, Chao CC, Chung HY, Kannagi R., Free PMC Article | 01/16/2021 |
| B3GALT5 knockout alters gycosphingolipid profile and facilitates transition to human naive pluripotency. | B3GALT5 knockout alters gycosphingolipid profile and facilitates transition to human naïve pluripotency.
Lin RJ, Kuo MW, Yang BC, Tsai HH, Chen K, Huang JR, Lee YS, Yu AL, Yu J., Free PMC Article | 01/9/2021 |
| In patients with hepatocellular carcinoma, Kaplan Meier survival analysis showed significantly shorter relapse-free survival for those with high expression of B3GALT5 and shorter overall survival. | High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma.
Kuo HH, Lin RJ, Hung JT, Hsieh CB, Hung TH, Lo FY, Ho MY, Yeh CT, Huang YL, Yu J, Yu AL., Free PMC Article | 07/20/2019 |
| Here we show that the expression of beta3GalT5 significantly correlates with tumor progression and poor survival in patients, and the globo-series GSLs in breast cancer cells form a complex in membrane lipid raft with caveolin-1 (CAV1) and focal adhesion kinase (FAK) which then interact with AKT and receptor-interacting protein kinase (RIP), respectively | Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer.
Chuang PK, Hsiao M, Hsu TL, Chang CF, Wu CY, Chen BR, Huang HW, Liao KS, Chen CC, Chen CL, Yang SM, Kuo CW, Chen P, Chiu PT, Chen IJ, Lai JS, Yu CT, Wong CH., Free PMC Article | 05/4/2019 |
| CA19.9 appears as a physiological product whose synthesis strongly depends on the tissue specific and epigenetically-regulated expression of B3GALT5 and ST3GAL3. | Unexpected distribution of CA19.9 and other type 1 chain Lewis antigens in normal and cancer tissues of colon and pancreas: Importance of the detection method and role of glycosyltransferase regulation.
Aronica A, Avagliano L, Caretti A, Tosi D, Bulfamante GP, Trinchera M. | 11/4/2017 |
| Data conclude that HNF1alpha/beta are necessary but insufficient to activate and regulate B3GALT5 LTR transcription, which depends on unknown regulatory elements that are active when methylated and located outside of and far from the LTR promoter. | Transcriptional control of the B3GALT5 gene by a retroviral promoter and methylation of distant regulatory elements.
Zulueta A, Caretti A, Signorelli P, Dall'olio F, Trinchera M. | 03/29/2014 |
| Chromatin immunoprecipitation assays on beta3Gal-T5 promoter showed that histone H3K4 trymethylation, H3K79 dimethylation, and H3K9-14 acetylation are high in cells expressing the transcript. | DNA methylation and histone modifications modulate the β1,3 galactosyltransferase β3Gal-T5 native promoter in cancer cells.
Caretti A, Sirchia SM, Tabano S, Zulueta A, Dall'Olio F, Trinchera M. | 07/14/2012 |
| The B3GALT5 promoter is activated by serum depletion according to promoter reporter assays in HEK 293 cells. | Functional analysis and identification of cis-regulatory elements of human chromosome 21 gene promoters.
Warnatz HJ, Querfurth R, Guerasimova A, Cheng X, Haas SA, Hufton AL, Manke T, Vanhecke D, Nietfeld W, Vingron M, Janitz M, Lehrach H, Yaspo ML., Free PMC Article | 09/14/2011 |
| Observational study and genome-wide association study of gene-disease association. (HuGE Navigator) | Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept.
Hamshere ML, Green EK, Jones IR, Jones L, Moskvina V, Kirov G, Grozeva D, Nikolov I, Vukcevic D, Caesar S, Gordon-Smith K, Fraser C, Russell E, Breen G, St Clair D, Collier DA, Young AH, Ferrier IN, Farmer A, McGuffin P, Wellcome Trust Case Control Consortium, Holmans PA, Owen MJ, O'Donovan MC, Craddock N., Free PMC Article | 08/12/2009 |
| the enhanced expression of beta 3GalT5 is sufficient to promote in vivo extension of type 1 chains by furnishing a significantly higher amount of type 1 chain precursors relative to competing type 2 chains. | Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.
Lin CH, Fan YY, Chen YY, Wang SH, Chen CI, Yu LC, Khoo KH. | 01/21/2010 |
| We found beta3Gal-T4 and T5 enzymatic activity in ovarian cancer tissues, indicating that these enzymes are expressed at least in ovarian cancer | Beta1,3-galactosyltransferases-4/5 are novel tumor markers for gynecological cancers.
Seko A, Kataoka F, Aoki D, Sakamoto M, Nakamura T, Hatae M, Yonezawa S, Yamashita K. | 01/21/2010 |
| case study of the endogenous retrovirus long terminal repeat promoter of this enzyme | Endogenous retrovirus long terminal repeats as ready-to-use mobile promoters: the case of primate beta3GAL-T5.
Dunn CA, van de Lagemaat LN, Baillie GJ, Mager DL. | 01/21/2010 |